## 3 Results
### Anticancer Studies of Eugenol and Isoeugenol  
_LoVo cell line_  
The results show the anticancer properties of eugenol and isoeugenol on the LoVo cell line, measured as the percentage of cell survival and at concentrations in the range of 10-200 ng/mL with respect to the control system, where a value of 100% viable cells was assumed (Figure 6). At the low concentrations (10-20 ng/mL), both eugenol and isoeugenol showed little stimulatory effect on the proliferation and/or mitochondrial enzyme activity (about 4% and 7%). On the other hand, from the concentration level of 30 ng/mL, the cytostatic/cytotoxic effect was already observed. The determined anticancer curves show that the cytotoxic effect increases noticeably with the increase in the concentrations of both eugenol and isoeugenol. The formulas of the determined regression curves made it possible to determine the IC50 values (for which the growth and proliferation of cells in culture are halted by 50%, in relation to the growth of the control cells) for both compounds which are, respectively: 92.34 ng/mL for eugenol and 89.98 IC50 for isoeugenol. There were no statistically significant differences between the effects of these compounds on the LoVo line (Figure 7). _U87 MG cell line_  
The analogous anticancer studies of eugenol and isoeugenol were carried out using the U87 MG line. As in the case of the LoVo line, the effect of the increased proliferation and/or mitochondrial enzyme activity was observed in the concentration range of 10-20 ng/mL--it was also more pronounced at 14 and 17%, respectively. To be sure of the observed results, a blank sample was tested (medium, DMSO solvent, and test compound), but no additional reduction in MTT to formazan was confirmed. The cytotoxic effect observed from a concentration of 40 ng/mL and the determined anticancer curves show that it increases dynamically with the increase in the concentrations of both eugenol and isoeugenol. The formulas of the determined regression curves allowed us to determine the IC50 values for both compounds which are, respectively: 72.59 ng/mL for eugenol and 69.28 IC50 for  
Figure 6: Anticancer profile of the LoVo cell line (human colon cancer cells) treated with varying concentrations of eugenol (EU) and isoeugenol (ISO-EU) compared to the untreated control samples. The results show the anticancer of eugenol and isoeugenol, measured as the percentage of cell survival at the concentrations ranging from 10 to 200 ng/mL, with respect to the control system, where 100% cell viability was assumed. The MTT assay was used to assess the cell viability after 72 h of incubation, demonstrating the impact of these compounds on cell survival. isoeugenol. There were no statistically significant differences between the effects of these compounds on the U87 MG line (Figures 8 and 9). Figure 8: Anticancer profile of the U87 MG cell line (human glioma cells) treated with varying concentrations of eugenol (EU) and isoeugenol (ISO-EU) compared to the untreated control samples. The results show the anticancer properties of eugenol and isoeugenol, measured as the percentage of cell survival at the concentrations ranging from 10 to 200 ng/mL, with respect to the control system, where 100% cell viability was assumed. The MTT assay was used to assess the cell viability after 72 h of incubation, demonstrating the impact of these compounds on cell survival. Figure 7: Anticancer profile of the LoVo cell line (human colon cancer cells) treated with eugenol (EU) and isoeugenol (ISO-EU) in the concentration range from 10 to 200 ng/mL. The graph illustrates the dose-dependent reduction in cell survival with a linear approximation of the data points, indicating a consistent, linear relationship between the concentration of these compounds and the decrease in cell viability. The results indicate that both the LoVo and U87 MG lines are sensitive to the effects of eugenol and isoeugenol. Both compounds induce a very similar cytotoxic effect on the line.